Urogen Pharma (NASDAQ:URGN) Receives $36.67 Consensus PT from Analysts

Urogen Pharma (NASDAQ:URGN) has earned an average rating of “Moderate Buy” from the seven analysts that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $39.50.

Several equities analysts recently commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Urogen Pharma in a research report on Monday, April 20th. HC Wainwright reissued a “buy” rating and set a $45.00 price target on shares of Urogen Pharma in a research report on Wednesday, June 3rd. Jefferies Financial Group raised Urogen Pharma to a “strong-buy” rating in a research report on Friday, April 24th. D. Boral Capital reissued a “buy” rating and set a $33.00 price target on shares of Urogen Pharma in a research report on Tuesday, March 31st. Finally, LADENBURG THALM/SH SH initiated coverage on Urogen Pharma in a research note on Monday, May 11th. They set a “buy” rating and a $43.00 target price for the company.

Insider Activity

In other news, insider Mark Schoenberg sold 5,222 shares of Urogen Pharma stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $27.30, for a total transaction of $142,560.60. Following the sale, the insider directly owned 139,763 shares of the company’s stock, valued at approximately $3,815,529.90. The trade was a 3.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 4.80% of the company’s stock.

Hedge Funds Weigh In On Urogen Pharma

A number of institutional investors have recently made changes to their positions in URGN. Paradigm Biocapital Advisors LP acquired a new position in shares of Urogen Pharma in the 3rd quarter valued at approximately $84,111,000. Soleus Capital Management L.P. acquired a new position in shares of Urogen Pharma in the 2nd quarter valued at approximately $29,934,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of Urogen Pharma in the 4th quarter valued at approximately $26,350,000. MPM Bioimpact LLC raised its position in shares of Urogen Pharma by 597.3% in the 4th quarter. MPM Bioimpact LLC now owns 941,378 shares of the company’s stock valued at $22,047,000 after purchasing an additional 806,378 shares in the last quarter. Finally, TCG Crossover Management LLC acquired a new position in shares of Urogen Pharma in the 3rd quarter valued at approximately $14,311,000. 91.29% of the stock is owned by institutional investors and hedge funds.

Urogen Pharma Stock Performance

Shares of NASDAQ:URGN opened at $30.86 on Tuesday. The stock has a 50-day simple moving average of $25.96 and a 200-day simple moving average of $22.86. The stock has a market capitalization of $1.50 billion, a P/E ratio of -11.22 and a beta of 1.59. Urogen Pharma has a 1 year low of $12.61 and a 1 year high of $32.37.

Urogen Pharma (NASDAQ:URGN) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.01. The company had revenue of $50.96 million for the quarter, compared to analyst estimates of $44.83 million. Analysts predict that Urogen Pharma will post -0.98 earnings per share for the current year.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.